Abstract
Purpose
To determine the prevalence of substance use disorders (SUDs) in patients with schizophrenia in a sample from South Africa and compare the clinical and demographic correlates in those with and without co-occurring SUDs.
Methods
Patients with schizophrenia were interviewed using the Xhosa version SCID-I for DSM-IV. We used logistic regression to determine the predictors of SUDs.
Results
In the total sample of 1420 participants, SUDs occurred in 47.8%, with the most prevalent SUD being cannabis use disorders (39.6%), followed by alcohol (20.5%), methaqualone (6.2%), methamphetamine (4.8%) and other SUDs (cocaine, ecstasy, opioids, 0.6%). Polydrug use occurred in 40%, abuse occurred in 13.5%, and 39.6% had at least one substance dependence diagnosis. Significant predictors of any SUD were younger age (41–55 vs. 21–30: OR = 0.7, 95% CI = 0.5–0.9), male sex (OR = 8.6, 95% CI = 5.1–14.6), inpatient status (OR = 1.7, 95% CI = 1.3–2.1), post-traumatic stress symptoms (OR = 4.6, 95% CI = 1.6–13.3), legal (OR = 3.4, 95% CI = 2.0–5.5) and economic problems (OR = 1.4, 95% CI = 1.0–2.0). Methamphetamine use disorders occurred significantly less often in the Eastern compared to the Western Cape provinces. Inpatient status and higher levels of prior admissions were significantly associated with cannabis and methamphetamine use disorders. Post-traumatic stress symptoms were significantly associated with alcohol use disorders. Anxiety disorders were associated with other SUDs.
Conclusion
SUDs occurred in almost half of the sample. It is important for clinicians to identify the presence of SUDs as their presence is associated with characteristics, such as male sex, younger age, inpatient status, more prior hospitalisations, legal and economic problems, PTSD symptoms and anxiety.
Similar content being viewed by others
References
Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG (2005) The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 112(2):141–148. https://doi.org/10.1111/j.1600-0447.2005.00554.x
Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G (2007) Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry 68(5):767–774
Cantor-Graae E, Nordstrom LG, McNeil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48(1):69–82
Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2009) Prevalence of alcohol use disorders in schizophrenia—a systematic review and meta-analysis. Acta Psychiatr Scand 120(2):85–96. https://doi.org/10.1111/j.1600-0447.2009.01385.x
Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36(6):1115–1130. https://doi.org/10.1093/schbul/sbp031
Sara GE, Large MM, Matheson SL, Burgess PM, Malhi GS, Whiteford HA, Hall WD (2015) Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Zeal J Psychiatry 49(2):106–117. https://doi.org/10.1177/0004867414561526
Ayano G (2019) Co-occurring medical and substance use disorders in patients with schizophrenia: a systematic review. Int J Ment Health 48(1):62–76. https://doi.org/10.1080/00207411.2019.1581047
Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB (2018) Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend 191:234–258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
Gut-Fayand A, Dervaux A, Olie JP, Loo H, Poirier MF, Krebs MO (2001) Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res 102(1):65–72
Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O'Callaghan E (2000) The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta Psychiatr Scand 101(6):452–456
Cuffel BJ, Heithoff KA, Lawson W (1993) Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Community Psychiatry 44(3):247–251
Jimenez-Castro L, Hare E, Medina R, Raventos H, Nicolini H, Mendoza R, Ontiveros A, Jerez A, Munoz R, Dassori A, Escamilla M (2010) Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry. Schizophr Res 120(1–3):87–94. https://doi.org/10.1016/j.schres.2010.02.1053
Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, Stroup TS (2011) Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res 132(2–3):177–182. https://doi.org/10.1016/j.schres.2011.07.032
Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 67(2–3):157–166. https://doi.org/10.1016/s0920-9964(02)00523-6
Rush B, Koegl CJ (2008) Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psychiatry 53(12):810–821. https://doi.org/10.1177/070674370805301207
Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM (2003) Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res 61(1):89–95
Scheller-Gilkey G, Moynes K, Cooper I, Kant C, Miller AH (2004) Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res 69(2–3):167–174
Seedat F, Roos JL, Pretorius HW, Karayiorgou M, Nel B (2007) Prevalence and clinical characteristics of obsessive-compulsive disorder and obsessive compulsive symptoms in Afrikaner schizophrenia and schizoaffective disorder patients. Afr J Psychiatry (Johannesbg) 10(4):219–224
Shoval G, Zalsman G, Apter A, Diller R, Sher L, Weizman A (2007) A 10-year retrospective study of inpatient adolescents with schizophrenia/schizoaffective disorder and substance use. Compr Psychiatry 48(1):1–7. https://doi.org/10.1016/j.comppsych.2006.05.002
Carra G, Crocamo C, Borrelli P, Popa I, Ornaghi A, Montomoli C, Clerici M (2015) Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders: findings from the “Psychiatric and Addictive Dual Disorder in Italy (PADDI)” Study. Compr Psychiatry 58:152–159. https://doi.org/10.1016/j.comppsych.2014.11.021
Compton MT, Simmons CM, Weiss PS, West JC (2011) Axis IV psychosocial problems among patients with psychotic or mood disorders with a cannabis use disorder comorbidity. Am J Addict 20(6):563–567. https://doi.org/10.1111/j.1521-0391.2011.00184.x
Compton MT, Weiss PS, West JC, Kaslow NJ (2005) The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol 40(12):939–946. https://doi.org/10.1007/s00127-005-0964-4
Helseth V, Lykke-Enger T, Johnsen J, Waal H (2009) Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nord J Psychiatry 63(1):72–77. https://doi.org/10.1080/08039480802450439
Paruk S, Burns JK, Caplan R (2013) Cannabis use and family history in adolescent first episode psychosis in Durban, South Africa. J Child Adolesc Ment Health 25(1):61–68. https://doi.org/10.2989/17280583.2013.767264
Taukoor B, Paruk S, Karim E, Burns JK (2017) Substance use in adolescents with mental illness in Durban, South Africa. J Child Adolesc Ment Health 29(1):51–61. https://doi.org/10.2989/17280583.2017.1318395
Vos PJ, Cloete KJ, le Roux A, Kidd M, Jordaan GP (2010) A retrospective review of trends and clinical characteristics of methamphetamine-related acute psychiatric admissions in a South African context. Afr J Psychiatry 13(5):390–394
Weich L, Pienaar W (2009) Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. Afr J Psychiatry 12(3):213–217
First M, RL S, M G, JBW W (1994) Structured clinical interview for DSM-IV Axis I disorders-Patient Edition (SCID-I-P, version 2)
https://www.scid4.org Structured Clinical Interview for DSM-IV. Biometrics Research Department. Accessed 15 Jan 2018
Campbell MM, Susser E, Mall S, Mqulwana SG, Mndini MM, Ntola OA, Nagdee M, Zingela Z, Van Wyk S, Stein DJ (2017) Using iterative learning to improve understanding during the informed consent process in a South African psychiatric genomics study. PLoS ONE 12(11):e0188466. https://doi.org/10.1371/journal.pone.0188466
Mall S, Platt JM, Temmingh H, Musenge E, Campbell M, Susser E, Stein DJ (2019) The relationship between childhood trauma and schizophrenia in the Genomics of Schizophrenia in the Xhosa people (SAX) study in South Africa. Psychol Med. https://doi.org/10.1017/s0033291719001703
Koen L, Niehaus DJ, Wright G, Warnich L, De Jong G, Emsley RA, Mall S (2012) Chromosome 22q11 in a Xhosa schizophrenia population. S Afr Med J 102(3 Pt 1):165–166. https://doi.org/10.7196/samj.5326
South African Institute of Race Relations. South African Survey Online (2003) www.irr.org.za. Accessed 15 Jan 2014
Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33(6):766–771
Sartorius N, Janca A (1996) Psychiatric assessment instruments developed by the World Health Organization. Soc Psychiatry Psychiatr Epidemiol 31(2):55–69
Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC (2007) A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 64(8):966–974. https://doi.org/10.1001/archpsyc.64.8.966
Rubin D (1987) Multiple imputation for nonresponse in surveys. Wiley, New York
StataCorp (2013) Stata statistical software: release 13. StataCorp LP, College Station
Thungana Y, Zingela Z, van Wyk S (2019) First-episode psychosis and substance use in Nelson Mandela Bay: findings from an acute mental health unit. S Afr J Psychiatry 25:1372. https://doi.org/10.4102/sajpsychiatry.v25i0.1372
Herman AA, Stein DJ, Seedat S, Heeringa SG, Moomal H, Williams DR (2009) The South African Stress and Health (SASH) study: 12-month and lifetime prevalence of common mental disorders. S Afr Med J 99(5 Pt 2):339–344
Gregg L, Barrowclough C, Haddock G (2007) Reasons for increased substance use in psychosis. Clin Psychol Rev 27(4):494–510. https://doi.org/10.1016/j.cpr.2006.09.004
Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiat 79(7):549–556. https://doi.org/10.1016/j.biopsych.2015.08.001
Mané A, Fernández-Expósito M, Bergé D, Gómez-Pérez L, Sabaté A, Toll A, Diaz L, Diez-Aja C, Perez V (2015) Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Psychiatry Res 229(1–2):70–74. https://doi.org/10.1016/j.psychres.2015.07.070
Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC (2014) Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Zeal J Psychiatry 48(11):1036–1047. https://doi.org/10.1177/0004867414533838
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA (2006) Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194(3):164–172. https://doi.org/10.1097/01.nmd.0000202575.79453.6e
Pluddemann A, Dada S, Parry CD, Kader R, Parker JS, Temmingh H, van Heerden S, de Clercq C, Lewis I (2013) Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. Afr J Psychiatry (Johannesbg) 16(1):45–49
Hobkirk AL, Watt MH, Myers B, Skinner D, Meade CS (2016) A qualitative study of methamphetamine initiation in Cape Town, South Africa. Int J Drug Pol 30:99–106. https://doi.org/10.1016/j.drugpo.2015.10.006
Morgan N, Mall S (2019) Pathways between urbanization and harmful substance use. Curr Opin Psychiatry 32(3):218–223. https://doi.org/10.1097/yco.0000000000000488
Saban A, Flisher AJ, Grimsrud A, Morojele N, London L, Williams DR, Stein DJ (2014) The association between substance use and common mental disorders in young adults: results from the South African Stress and Health (SASH) Survey. Pan Afr Med J 17(Suppl 1):11. https://doi.org/10.11694/pamj.supp.2014.17.1.3328
O'Hare T, Sherrer MV, Shen C (2006) Subjective distress from stressful events and high-risk behaviors as predictors of PTSD symptom severity in clients with severe mental illness. J Trauma Stress 19(3):375–386. https://doi.org/10.1002/jts.20131
O'Hare T, Sherrer M (2011) Drinking motives as mediators between PTSD symptom severity and alcohol consumption in persons with severe mental illnesses. Addict Behav 36(5):465–469. https://doi.org/10.1016/j.addbeh.2011.01.006
Andrade C (2016) Cannabis and neuropsychiatry, 2: the longitudinal risk of psychosis as an adverse outcome. J Clin Psychiatry 77(6):e739–742. https://doi.org/10.4088/JCP.16f10918
Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB (2009) Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 190(4 Suppl):S22–25
Ouellet-Plamondon C, Abdel-Baki A, Salvat E, Potvin S (2017) Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychol Med 47(14):2461–2471. https://doi.org/10.1017/s0033291717000976
Acknowledgements
We wish to acknowledge the support of Dr Adele Pretorius, project manager of the SAX study as well as the Cape Town and New York based SAX data teams, notably Megan Malan, Bronwyn Malagas, Howard Andrews and Kim Fader for their assistance with data management, quality control and access. We would like to thank Dr. Adam Baldinger, Prof. Mo Nagdee and Prof. Zuki Zingela for their support and groundwork in the Western and Eastern Cape SAX study sites.
Funding
The SAX study received funding from the National Institute of Mental Health (NIMH: Grant No. 5UO1MH096754) and is a member of the Human Heredity and Health in Africa Consortium (H3 Africa) (https://www.h3africa.org/). SM has received support from the Harry Crossley and National Research Foundation of South Africa’s post-doctoral research fellowships, a Claude Leon Foundation early career research award and a seed award from the School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. SM has received funding from the Columbia University Southern African AIDS International Training/Research Program.
Author information
Authors and Affiliations
Contributions
HT conceptualised the study, analysed the data and wrote the first and subsequent drafts. All other authors contributed to the first and subsequent drafts.
Corresponding author
Ethics declarations
Conflict of interest
HT, ES, SM, MC, and GS and have not received any financial or commercial related compensation that can be considered to represent a conflict of interest. DJS is supported by the Medical Research Council of South Africa and has received research grants and/or consultancy honoraria from: Abbott, Astrazeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda, Tikvah, and Wyeth. DJS is also on the scientific advisory board of the TLC Foundation for Body-Focused Repetitive Behaviours, the Anxiety and Depression Association of America (ADAA), and the South African Depression and Anxiety Support Group. SM has received incentive funding for rated researchers from the South African National Research Foundation (NRF) (Grant No. 119375).
Ethics approval
The Human Ethics Committee of the Faculty of Health Sciences, University of Cape Town, South Africa granted approval to the study (HREC No. 049/2013). In addition, ethical approval was also obtained from the Walter Sisulu University Research Ethics and Biosafety Committee, The Rhodes University Ethical Standards Committee, The Columbia University Internal Review Board and the University of Washington Institutional Review Board. To ensure that participants understood and had sufficient decisional capacity to understand the nature of the study, the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire [30] was administered to all participants.
Rights and permissions
About this article
Cite this article
Temmingh, H., Susser, E., Mall, S. et al. Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 56, 695–706 (2021). https://doi.org/10.1007/s00127-020-01942-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00127-020-01942-5